Peter Goodfellow has recently been appointed Senior Vice-President in the Research and Development division of the pharmaceutical company SmithKline Beecham. Dr Goodfellow's most outstanding contribution to research has been the identification of genes that control the development of maleness in mammals. He has also had a continued involvement in the development of strategies currently used in human molecular genetics, and more recently has had a major role in setting up a biotechnology company. His combination of commercial experience, scientific expertise and a unique irreverence should bring a new dimension to the management of SmithKline Beecham in the next few years.
Like many English lads, during his youth Dr Goodfellow dreamt of serving his country on the soccer pitch. At the age of eighteen, he realized that this was unlikely to happen and was granted a place in the microbiology course at the University of Bristol. Having little idea of what microbiology actually was, he read a textbook on the train to his interview and then proceeded to deliver a one hour discourse on how microorganisms could be used to extract gold.
At Bristol, he discovered a natural flair for understanding and thinking within the framework of molecular biology and consequently excelled at his studies. At the end of his Honours year he was advised that eukaryotic genetics was likely to offer a more promising future than prokaryotic, and he accepted a postgraduate position in Walter Bodmer's laboratory at the University of Oxford. Dr Goodfellow's introduction to human molecular genetics came with his graduate project on the genetic relationship of components of the immune system. It was during this time that he began using somatic hybrid cell lines for gene mapping. In 1975 he received his PhD from Oxford University and Julia Goodfellow, his partner, became the first woman to obtain a PhD from England's Open University. Together they set off for Stanford University, where Peter Goodfellow took up a position with Hugh McDevitt to study the serology of the mouse t locus.
This was a difficult time for Dr Goodfellow as his results went against the established beliefs in the field. At the end of his time at Stanford, however, he had managed to learn some developmental biology from friends at UCSF and had also used his knowledge of somatic cell hybridization to introduce techniques for monoclonal antibody production into the San Francisco bay area. He had also been 'gobbed on' by Sid Vicious at the Sex Pistol's final concert.
He returned to London to take up a position at the Imperial Cancer Research Fund's laboratories, while Julia Goodfellow took up a post in X-ray crystallography at Birkbeck College. As a newcomer to the ICRF, he had to fight for both space and acceptance in what was, then, quite a conservative establishment. This was made plain when he heard his lab -two slightly off-beat research assistants and himselfdescribed as 'a poof, a punk and a weirdo'.
While awaiting the arrival of mouse strains from America to start one of his projects, Dr Goodfellow began using somatic cell hybrids to map the chromosomal position of genes encoding antigens that are over-expressed in cancer cells. One of these genes mapped close to the proposed testis-determining factor (TDF) gene, the locus on the Y chromosome that initiates male development. The Goodfellow lab then began a number of positional cloning strategies to isolate a particular candidate for the TDF gene but was beaten to it by David Page's group from the Massachusetts Institute of Technology.
Although Dr Goodfellow began spending more time hidden under his desk, reading poetry to his staff and making them endless pots of extraordinarily strong coffee, he was not deterred. His group continued to work on the molecular genetics of mammalian sex determination, and in 1989 obtained results which suggested that the gene isolated by Page's group was not the 'master' male-determining gene. So the hunt for the TDF gene began again. This time, a team led by Andrew Sinclair, a postdoc in Dr Goodfellow's lab, successfully isolated the correct gene and, in collaboration with Robin Lovell-Badge's group at the National Institute for Medical Research at Mill Hill, demonstrated its male-determining activity.
With the successful isolation of the mammalian TDF gene came a number of job offers -but an offer from an American university was withdrawn after Dr Goodfellow presented his interview seminar using the pointer as his sole visual aid, while sitting cross-legged on a table at the front of the auditorium. He eventually accepted an offer to head the Department of Genetics at the University of Cambridge, England.
Determined to make his mark from the beginning, he immediately began reading poetry to students,
